Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999315 | Urologic Oncology: Seminars and Original Investigations | 2016 | 9 Pages |
Abstract
Approximately a quarter of the mRCC patients are classified into different risk groups of the IMDC model following targeted therapy administration in the first-line and second-line settings. There is a significant difference in overall survival of subgroups after the IMDC model reclassifications.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Nobuyuki M.D., Ph.D., Ryuichi M.D., Ph.D., Suguru M.D., Ph.D., Keiichi M.D., Ph.D., Yota M.D., Ayako M.D., Yujiro M.D., Yasumasa M.D., Masayuki M.D., Kent M.D., Ph.D., Shuji M.D., Ph.D., Ken M.D., Ph.D., Tetsuo M.D., Ph.D., Takeshi M.D., Tomohiko M.D.,